GI Dynamics
134 articles about GI Dynamics
-
GI Dynamics Announces Company Rebrand as Morphic Medical® Reintroducing Flagship Product as RESET®
7/11/2023
GI Dynamics, creator of the world's first medical device designed to target the underlying cause of type 2 diabetes, is proud to announce its rebrand to Morphic Medical and the introduction of RESET, formally known as EndoBarrier®.
-
GI Dynamics Announces an Update to the Worldwide Registry Data for 1,022 Patients Recently Published in Diabetes Care, the Journal of the American Diabetes Association
4/4/2023
GI Dynamics® Inc. is pleased to announce updated positive data from the Association of British Clinical Diabetologists Worldwide EndoBarrier Registry showing improvements in weight, glycemic control, blood pressure, and cholesterol.
-
GI Dynamics Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India
2/13/2023
GI Dynamics® Inc., a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce the first patient in the India I-STEP clinical study has been treated at Apollo Speciality Hospital in Chennai, India in January.
-
GI Dynamics Announces the Presentation of Updated Data Sets at the 2022 Meeting of the American Diabetes Association
7/14/2022
GI Dynamics® Inc. , a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry and data from use within the National Health Service.
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
6/15/2022
GI Dynamics announced results from a multicenter study evaluating GI Dynamic’s EndoBarrier® System intended for patients who do not have adequate control of their type 2 diabetes and obesity through their current medication and lifestyle.
-
GI Dynamics Announces Approval of the I-STEP Clinical Study in India
1/31/2022
Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity.
-
First Patient Enrolled in the US STEP-1 Clinical Trial of EndoBarrier at Michigan Medicine
1/28/2020
GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the first patient in the United States STEP-1 clinical trial has been enrolled at Michigan Medicine in Ann Arbor, Michigan.
-
GI Dynamics Announces Institutional Review Board Approval for EndoBarrier Pivotal Trial
2/14/2019
GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has received Institutional Review Board approval to conduct its pivotal trial of EndoBarrier for type 2 diabetes and obesity.
-
GI Dynamics Appoints Vice President of Clinical and Regulatory Affairs
1/4/2019
GI Dynamics® Inc. is pleased to announce the appointment of Stephen Linhares to the position of vice president of clinical and regulatory affairs.
-
GI Dynamics Announces Agreement with Apollo Sugar to Study EndoBarrier in India
11/27/2018
Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity.
-
GI Dynamics Announces Close of Second Tranche of Placement and Grant of Options to CEO
11/16/2018
GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that, following stockholder approval obtained on 30 October 2018 at the Company’s Special Meeting, it has successfully completed the issue of the CHESS Depositary Interests (CDIs), the subject of the second tranche of the Placement that was detailed further in the Company’s 20 September 2018 announcement.
-
GI Dynamics Announces Selection of New Notified Body
10/4/2018
GI Dynamics, Inc. is pleased to announce the selection of Intertek as the company’s notified body to continue working toward attaining the EndoBarrier CE Mark.
-
GI Dynamics Announces AUD $6.9m Private Placement to be Completed in Two Tranches
9/20/2018
GI Dynamics, Inc. is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary Interests (CDIs) of the Company
-
GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial
8/13/2018
Pivotal trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity
-
GI Dynamics Announces AUD $2.05 M Private Placement and Close of First Tranche of AUD ~$1 M
1/23/2018
The issue of CDIs under the Placement will occur in two tranches.
-
GI Dynamics, Inc. Provides 2017 Review and 2018 Business Outlook
1/15/2018
GI Dynamics is preparing to submit an Investigational Device Exemption (IDE1) application to the US Food and Drug Administration (FDA) for a new pivotal trial of the EndoBarrier.
-
GI Dynamics Announces Change to Board of Directors - Nov. 27, 2017
11/27/2017
The company received the resignation of GI Dynamics non-executive directors Anne Keating and Graham Bradley.
-
GI Dynamics to Provide Corporate Update and 2017 Third Quarter Results
11/20/2017
The company will host a webcast at 4 PM EST 21 November 2017 | 8 AM AEDT 22 November 2017.
-
The company has been working diligently to address the issues raised by SGS.
-
GI Dynamics Release: IK+EM Study Released At EASD Shows Similar Outcomes Between Gastric Plication And Endobarrier
9/25/2017